Abstract:Novel immunotherapies and small molecular inhibitors are transforming our approach to previously treated and newly diagnosed patients across the spectrum of non-Hodgkin lymphomas (NHLs). Anti-CD19 CAR T cells are now indicated for the treatment of relapsed/refractory aggressive B-cell lymphomas after at least two previous lines of therapy in which durable remissions are achieved in approximately 40% of previously incurable patients. Second-line chemoimmunotherapy remains the standard of care at first relapse, but poor outcomes with conventional treatment in this setting creates an appealing rationale for earlier use of CAR T cells, which is currently under investigation, along with even earlier use in selected high-risk patients in the frontline setting. Other emerging immunotherapies include antibody-drug conjugates (ADCs), such as polatuzumab vedotin for multiple-relapsed diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine-rituximab. Multiple bispecific antibodies that bring malignant B cells in contact with effector T cells appear promising in early clinical trials and will likely emerge as off-the-shelf immunotherapy options. Chemotherapy-free small molecule-based regimens are increasingly available for mantle cell (MCLs) and follicular lymphomas (FLs). Bruton tyrosine kinase inhibitors (BTKi) now represent standard second-line therapy for MCL and are being investigated in combination and as initial therapy. Lenalidomide-rituximab is an active regimen in both FL and MCL and may be used in either relapsed/refractory or previously untreated disease. Three PI3K inhibitors are approved for multiple-relapsed FL and can induce durable remissions in patients with chemotherapy- and rituximab-refractory disease. Additional emerging targeted therapies include BCL2 inhibition in MCL and EZH2 inhibition in FL.

New targeted therapies for malignant lymphoma based on molecular heterogeneity

Targeting indolent non-Hodgkin lymphoma

[Lymphomas: A therapeutic update]

Novel targeted drugs for follicular and marginal zone lymphoma: a comprehensive review

Molecular classification of aggressive lymphomas—past, present, future

Investigational therapies targeting lymphocyte antigens for the treatment of non-Hodgkin's lymphoma

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma

Evolving molecular classification of aggressive B‐cell lymphoma

Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas

Overview of Targeted Drugs for Mature B-Cell Non-hodgkin Lymphomas

Investigational drugs for the treatment of diffuse large B-cell lymphoma

Learning from the failures of drug discovery in B-cell non-Hodgkin lymphomas and perspectives for the future: chronic lymphocytic leukemia and diffuse large B-cell lymphoma as two ends of a spectrum in drug development

Novel insights into the pathogenesis of molecular subtypes of diffuse large B-cell lymphoma and their clinical implications

Targeting MYC-driven lymphoma: lessons learned and future directions

ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma

Safety considerations with targeted therapy drugs for B-cell non-Hodgkin lymphoma

Beyond Chemotherapy: Present and Future Perspectives in the Treatment of Lymphoproliferative Disorders

Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)

New developments in the treatment of follicular lymphoma/ marginal zone lymphoma (according to the Congress of the American Society of Hematology – 2020)

Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level

Update: The molecular spectrum of virus-associated high-grade B-cell non-Hodgkin lymphomas